KalVista FY2023 net loss $92.9M; sebetralstat Phase 3 enrollment complete

KalVista Pharmaceuticals, Inc.

Phase 3 KONFIDENT trial achieved target enrollment (114 patients); data readout expected Q4 2023; NDA planned H1 2024.
Net loss FY2023 $92.9M ($3.33/share) vs $82.3M ($3.36/share); no revenue.
R&D expenses $80.3M (FY2023) vs $70.2M; G&A $30.6M vs $26.4M.
Cash, equivalents and marketable securities $149.4M; funded into 2025 after $58M registered direct offering.
Promoted Benjamin Palleiko to President; appointed Brian Pereira as Chairman.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KalVista Pharmaceuticals, Inc. reported fiscal year ended April 30, 2023 results: revenue No revenue was recognized, net income $92.9 million, EPS $(3.33) per weighted average basic and diluted share.

Period: fiscal year ended April 30, 2023
Revenue: No revenue was recognized
Net income: $92.9 million
EPS: $(3.33) per weighted average basic and diluted share
Result: reported results

Exact text from the filing

Net loss was $92.9 million, or $(3.33) per weighted average basic and diluted share for the fiscal year ended April 30, 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KalVista Pharmaceuticals, Inc. reported three months ended April 30, 2023 results: revenue No revenue was recognized, net income $26.3 million, EPS $(0.77) per weighted average basic and diluted share.

Period: three months ended April 30, 2023
Revenue: No revenue was recognized
Net income: $26.3 million
EPS: $(0.77) per weighted average basic and diluted share
Result: reported results

Exact text from the filing

Net loss was $26.3 million, or $(0.77) per weighted average basic and diluted share, for the three months ended April 30, 2023

View on SEC.gov

Browse all earnings releases →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-032300

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.